Related Experiment Video

Updated: Jul 27, 2026

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor
07:45

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor

Published on: June 27, 2011

Serum protein binding of desmethyl-methsuximide

N Wad1, B Bourgeois, G Krämer

  • 1Swiss Epilepsy Centre, Zurich, Switzerland.

Clinical Neuropharmacology
|August 12, 1999
PubMed

Insights

The active metabolite of methsuximide (MSM), desmethyl-methsuximide (DM-MSM), exhibits moderate serum protein binding. This finding is crucial for understanding drug efficacy and dosage in patients undergoing polytherapy.

Area of Science:

  • Pharmacology
  • Clinical Chemistry
  • Drug Metabolism

Background:

  • Methsuximide (MSM) is an anticonvulsant medication.
  • Desmethyl-methsuximide (DM-MSM) is the primary active metabolite of MSM.
  • Understanding drug-protein binding is essential for pharmacokinetics and therapeutic outcomes.

Purpose of the Study:

  • To determine the extent of serum protein binding for desmethyl-methsuximide (DM-MSM).
  • To investigate DM-MSM binding in patients receiving polytherapy.

Main Methods:

  • Ultrafiltration technique was employed to separate bound and unbound drug.
  • High-performance liquid chromatography (HPLC) was utilized for drug quantification.
  • Serum samples from 23 patients on polytherapy were analyzed.

Main Results:

  • Desmethyl-methsuximide (DM-MSM) demonstrated moderate serum protein binding.
  • The binding percentage ranged between 45% and 60% across the patient cohort.
  • Results were obtained from serum samples of patients on multiple medications.

Conclusions:

  • DM-MSM exhibits moderate protein binding in patients on polytherapy.
  • This moderate binding influences the free fraction of the drug, impacting its pharmacodynamics.
  • Further studies may explore the clinical implications of DM-MSM protein binding on anticonvulsant therapy.

More Related Videos

Low Molecular Weight Protein Enrichment on Mesoporous Silica Thin Films for Biomarker Discovery13:00

Low Molecular Weight Protein Enrichment on Mesoporous Silica Thin Films for Biomarker Discovery

Published on: April 17, 2012

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Concept Videos

Protein-Drug Binding: Determination Methods01:22

Protein-Drug Binding: Determination Methods

Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...